Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

A BPTF-specific PROTAC degrader enhances NK cell-based cancer immunotherapy

11 Feb 2025

Abstract excerpt

Natural killer (NK) cell-based immunotherapy shows promise in cancer treatment, but its efficacy remains limited, necessitating the development of novel strategies. In this study, we demonstrate that the epigenetic factor bromodomain PHD-finger containing transcription factor (BPTF) hinders hepatocellular carcinoma (HCC) recognition by NK cells through its PHD finger's interpretation of H3K4me3. We have generated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to CAR-T cell therapy research
Share to Peptidase Inhibition and Analysis
Share to Protein Degradation and Inhibitors

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 39935175
DOI: 10.1016/j.ymthe.2025.02.013

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 6 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

A BPTF-specific PROTAC degrader enhances NK cell-based cancer immunotherapyPMID 39935175Read ↗

BRD8 Disruption Unlocks Retrotransposon-Driven Tumor-Intrinsic Immunogenicity via Redistribution of Histone Acetylation in Liver CancerSemantic proximity Read ↗

Targeting the Undruggable: Recent Progress in PROTAC-Induced Transcription Factor DegradationSemantic proximity Read ↗

Destruction of DNA-binding proteins by programmable O’PROTAC: Oligonucleotide-based PROTACSemantic proximity Read ↗

Unleashing the Power of NR4A1 Degradation as a Novel Strategy for Cancer ImmunotherapySemantic proximity Read ↗

Acetylation Targeting Chimera Enables Acetylation of the Tumor Suppressor p53.Semantic proximity Read ↗

Ubiquitination in hepatocellular carcinoma immunitySemantic proximity Read ↗

Epstein-Barr virus protein BKRF4 restricts nucleosome assembly to suppress host antiviral responsesSemantic proximity Read ↗

Reinstating targeted protein degradation with DCAF1 PROTACs in CRBN PROTAC resistant settingsSemantic proximity Read ↗

Targeted Protein Degradation in Lung Cancer: The Emerging Role of PROTAC Technology and E3 LigasesSemantic proximity Read ↗

CRBN‐PROTACs in Cancer Therapy: From Mechanistic Insights to Clinical ApplicationsSemantic proximity Read ↗

The oncogenic fusion protein DNAJB1-PRKACA can be specifically targeted by peptide-based immunotherapy in fibrolamellar hepatocellular carcinomaSemantic proximity Read ↗

Hijacking Methyl Reader Proteins for Nuclear-Specific Protein DegradationSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.